<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701649</url>
  </required_header>
  <id_info>
    <org_study_id>CYT006-AngQb 02</org_study_id>
    <secondary_id>Eudract No. 2007-005843-93</secondary_id>
    <nct_id>NCT00701649</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension</brief_title>
  <official_title>A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytos Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytos Biotechnology AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CYT006-AngQb is a vaccine that induces a B-cell mediated immune response characterized by the&#xD;
      generation of specific antibodies (IgG and IgM) against Angiotensin II. The vaccine is&#xD;
      administered by subcutaneous injection.&#xD;
&#xD;
      The objectives of the study are:&#xD;
&#xD;
        -  To evaluate safety and tolerability of 5 s.c. injections of 300µg CYT006-AngQb with&#xD;
           Alhydrogel™ in patients with mild to moderate essential hypertension (hypertension Grade&#xD;
           I and II).&#xD;
&#xD;
        -  To assess pharmacodynamic effects, i.e. anti-Ang II immune response and renin-&#xD;
           angiotensin system (RAS) biomarkers.&#xD;
&#xD;
        -  To explore the effect on blood pressure using ABPM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events: quality, quantity, severity</measure>
    <time_frame>Throughout the study until week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in daytime, nighttime and 24-hour ambulatory blood pressure from baseline</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of IgG specific for angiotensin II</measure>
    <time_frame>Throughout the study untill week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of RAS-Biomarkers (plasma renin concentration, angiotensin II, aldosterone)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT006-AngQb</intervention_name>
    <description>s.c.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>s.c.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with mild to moderate essential hypertension (Grade I and Grade II) with mean&#xD;
             sitting office SBP =140-179 mmHg and/or mean sitting office DBP = 90-109 mmHg on 2&#xD;
             consecutive visits (screening and V1).&#xD;
&#xD;
          -  Daytime blood pressure above threshold for definition of hypertension in the screening&#xD;
             ABPM measurement (SBP &gt;135 mmHg).&#xD;
&#xD;
          -  Patients without current antihypertensive therapy.&#xD;
&#xD;
          -  Patients on antihypertensive therapy, which can be stopped.&#xD;
&#xD;
          -  18 to 69 years of age.&#xD;
&#xD;
          -  Male patients, or female patients without childbearing potential .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with &quot;very high added risk&quot; according to 2007 Guidelines for the Management&#xD;
             of Arterial Hypertension (Journal of Hypertension, 2007, 25:1105-1187), i.e. those&#xD;
             with:&#xD;
&#xD;
          -  grade III hypertension (mean sitting office SBP ≥180mmHg and/or mean sitting&#xD;
             DBP≥110mmHg)&#xD;
&#xD;
          -  history or presence of established cardiovascular or renal disease:&#xD;
&#xD;
          -  Ischemic stroke, cerebral hemorrhage, transient ischemic attack&#xD;
&#xD;
          -  Myocardial infarction, angina pectoris, coronary re-vascularization, heart failure&#xD;
&#xD;
          -  Peripheral artery disease&#xD;
&#xD;
          -  Diabetic nephropathy&#xD;
&#xD;
          -  Known autoimmune disease.&#xD;
&#xD;
          -  Severe allergy.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Women in childbearing age that are not surgically sterilized.&#xD;
&#xD;
          -  Patients with a history or current positive test for HIV infection, AIDS, or other&#xD;
             immunosuppressive disorders; hepatitis B or C.&#xD;
&#xD;
          -  Current diagnosis or history of malignancy.&#xD;
&#xD;
          -  Presence of suspicious lymphadenopathy or splenomegaly on physical examination.&#xD;
&#xD;
          -  Drug or alcohol abuse within the past 2 years.&#xD;
&#xD;
          -  Presence or history of relevant cardiovascular, renal, hepatic, pulmonary, endocrine,&#xD;
             autoimmune, neurological and psychiatric disease as judged by the investigator.&#xD;
&#xD;
          -  Any current or past disease or conditions (physical or mental) that would, in the&#xD;
             opinion of the investigator, interfere with the study procedures or interpretation of&#xD;
             the study data (e.g. workers in the night shift).&#xD;
&#xD;
          -  Previous participation in a clinical trial with a Qb based vaccine.&#xD;
&#xD;
          -  Use of an investigational drug within 3 months before enrolment, or planned use during&#xD;
             the whole study period.&#xD;
&#xD;
          -  Possible dependency of the patient on sponsor and/or investigator.&#xD;
&#xD;
          -  Planned active immunization 2 weeks before or 2 weeks after any study medication&#xD;
             vaccination.&#xD;
&#xD;
          -  Donation or loss &gt;=400 mL of blood within 8 weeks prior to dosing or major surgery&#xD;
             within past 2 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRS Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRS Mönchengladbach</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>D-41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Zentrum Römerhof</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>December 1, 2009</last_update_submitted>
  <last_update_submitted_qc>December 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Jürg Nussberger</name_title>
    <organization>Hôpital Nestlé 6027, CHUV, CH-1011 Lausanne, Switzerland</organization>
  </responsible_party>
  <keyword>mild essential hypertension</keyword>
  <keyword>moderate essential hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

